Metabolon, the world leader in metabolomics, today announced that Dr. Jan Lundberg, Ph.D. has joined its Board of Directors. Dr. Lundberg brings significant experience leading large global research and development organizations, most recently as President of Lilly Research Labs and Head of R&D at Eli Lilly. Lundberg will serve as an independent director to Metabolon.
Dr. Lundberg is a luminary within the pharmaceutical research and development community. Dr Lundberg joins the Metabolon Board at a key time for our company, and his industry experience and scientific insights will be a valuable asset as we continue to deliver world-class metabolomics data, solutions and insights, said Rohan Hastie, Ph.D., Chief Executive Officer of Metabolon.
Lundberg has two decades of executive leadership experience in the pharmaceutical sector and held c-suite positions with leading companies including Eli Lilly and AstraZeneca. He has overseen the development of more than 200 candidate drugs, with 22 approved products across multiple therapeutic areas. Before joining AstraZeneca, Dr. Lundberg held the position of Professor of Pharmacology at the Karolinska Institute in Solna, Sweden.
Having watched Metabolon over the past few years, the companys progress in becoming the global leader in metabolomics has been formidable, said Dr. Lundberg. I am excited to join the Board and look forward to contributing to the teams growing success.
In addition to his significant industry experience, Dr. Lundberg is the co-founder of Aerocrine AB and currently serves on the boards of Ardelyx, Betagenon Image Analysis Group, and TB Alliance. He has also been a member of several governmental committees in both the European Union and the United States. Dr. Lundberg completed his undergraduate studies at the University of Gothenburg, earning a Bachelor of Science degree in Medicine, and his Ph.D. at the Karolinska Institute.
Metabolon is the world’s leading health technology company advancing metabolomics for precision medicine and every area of life sciences research. Metabolon’s Precision Metabolomics„¢ is a powerful technology for assessing health and is delivering biomarker discoveries, innovative diagnostic tests, and ground-breaking data in genomics and population health initiatives.
Almost every factor impacting the phenotype from genetics and the microbiome to disease and lifestyle exerts its influence by altering metabolite levels. By producing the most accurate, comprehensive picture of the metabolome, Metabolon helps answer some of biology’s most challenging questions.